A few placebo recipients responded against CS3 (14–28%), CS6 (0–7%) and LTB (0–14%) in plasma and/or ALS, as assessed by ECL and ELISA, respectively, but most responses were of low magnitudes and responses were mostly recorded against a single antigen and only in one type of specimen for each subject. Here, LTB is linked to amyotrophic lateral sclerosis.